FDA sends update reminding of valproate and birth defects

12/4/2009 | Medscape (free registration)

The FDA issued a reminder to health care providers that valproate sodium, valproic acid and divalproex sodium are strongly linked to birth defects. The agency said clinicians should talk to women of childbearing age about the risks of the medications and consider alternative therapies.

View Full Article in:

Medscape (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
In house Compliance Officer
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC